Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/38660
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rashid H. | en |
dc.contributor.author | Meredith I.T. | en |
dc.contributor.author | Nasis A. | en |
dc.date.accessioned | 2021-05-14T13:11:46Z | en |
dc.date.available | 2021-05-14T13:11:46Z | en |
dc.date.copyright | 2017 | en |
dc.date.created | 20170707 | en |
dc.date.issued | 2017-07-07 | en |
dc.identifier.citation | Heart Lung and Circulation. 26 (8) (pp 786-798), 2017. Date of Publication: August 2017. | en |
dc.identifier.issn | 1443-9506 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/38660 | en |
dc.description.abstract | Cardiovascular disease remains the leading cause of morbidity and mortality in developed nations, with elevated low-density lipoprotein-cholesterol (LDL-C) levels being a major modifiable risk factor for coronary atherosclerosis. While lipid-lowering therapies such as statins are effective in lowering LDL-C, a proportion of patients do not achieve target LDL-C goals with statins or are intolerant to statins necessitating other treatment options. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of agents that reduce LDL-C beyond the maximum achievable LDL-C reductions with statins, and have been well studied in different patient groups. However, there are concerns regarding their potential adverse effects and cost, given that morbidity and mortality benefits have not yet been demonstrated. This state-of-the art review provides an overview of the development of PCSK9 inhibitors, the evidence regarding their clinical efficacy in specific target populations, and highlights future trials and challenges that need to be addressed before PCSK9 inhibitors are widely adopted into contemporary clinical practice.Copyright © 2017 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ) | en |
dc.language | en | en |
dc.language | English | en |
dc.publisher | Elsevier Ltd | en |
dc.relation.ispartof | Heart Lung and Circulation | en |
dc.title | PCSK9 Monoclonal Antibodies in 2016: Current Status and Future Challenges. | en |
dc.type | Review | en |
dc.type.studyortrial | Review article (e.g. literature review, narrative review) | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1016/j.hlc.2016.12.005 | en |
dc.publisher.place | United Kingdom | en |
dc.identifier.pubmedid | 28286091 [http://www.ncbi.nlm.nih.gov/pubmed/?term=28286091] | en |
dc.identifier.source | 614738190 | en |
dc.identifier.institution | (Rashid, Meredith, Nasis) Monash Cardiovascular Research Centre, MonashHEART, Monash Health and Monash University Department of Medicine (MMC), Melbourne, Vic, Australia | en |
dc.description.address | A. Nasis, Monash Cardiovascular Research Centre, MonashHEART, Monash Health and Monash University Department of Medicine (MMC), Melbourne, Vic, Australia. E-mail: arthur.nasis@monashhealth.org | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2017 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | Lipid lowering therapies PCSK9 inhibitors Statins | en |
dc.identifier.authoremail | Nasis A.; arthur.nasis@monashhealth.org | en |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Review | - |
crisitem.author.dept | Cardiology (MonashHeart & Victorian Heart Institute) | - |
crisitem.author.dept | Cardiology (MonashHeart & Victorian Heart Institute) | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.